Management of Hyperkalemia in Hypertensive Patients

Introduction to Hyperkalemia Management

The European Society of Cardiology recommends continuing RAAS inhibitors (ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists) for hypertension management even in the presence of hyperkalemia, using newer potassium binders to maintain normokalemia 1, 2, 3

Patients with chronic kidney disease, diabetes mellitus, heart failure, and elderly patients are at higher risk of developing hyperkalemia 1, 2, 3
The incidence of hyperkalemia with RAAS inhibitor monotherapy is <2% in hypertensive patients without risk factors, but increases to 5-10% when administered to patients with heart failure or chronic kidney disease 1

Initial assessment should include checking potassium and renal function 7-10 days after starting or increasing RAAS inhibitor doses, and ongoing monitoring should be done at 1-2 weeks, 3 months, then every 6 months 2, 3
For patients with potassium levels >5.0-<6.5 mEq/L, maintain RAAS inhibitor therapy and initiate approved potassium-lowering agents (patiromer or sodium zirconium cyclosilicate) 1, 2, 3
For patients with potassium levels >6.5 mEq/L, temporarily discontinue or reduce RAAS inhibitor and initiate potassium-lowering agents as soon as possible 1, 2, 3

Patiromer and sodium zirconium cyclosilicate are recommended for the treatment of hyperkalemia, with patiromer having a slower onset of action but allowing for continuation of RAAS inhibitors 1, 3
Sodium zirconium cyclosilicate has a rapid onset of action and is suitable for urgent outpatient scenarios 3, 4

Calcium channel blockers, thiazide diuretics, and loop diuretics are preferred agents for the treatment of hypertension in patients with hyperkalemia 1, 4
Beta-blockers and potassium-sparing diuretics should be used with caution, as they can contribute to hyperkalemia 1, 4

Immediate interventions for life-threatening hyperkalemia include cardiac membrane stabilization with calcium gluconate, shifting potassium intracellularly with insulin and glucose, and removing potassium from the body with loop diuretics or hemodialysis 1, 2, 3

Continue RAAS inhibitors at optimal doses with concurrent potassium binder, and regularly monitor potassium and renal function 1, 2, 3
Dietary counseling and avoidance of nephrotoxins are also important for long-term management 3